{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nilsen TS"],"funding":["NCI NIH HHS"],"pagination":["1134-1141"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5953772"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["50(6)"],"pubmed_abstract":["PURPOSE:The purpose of this study was to explore whether methods adapted from oncology pharmacological trials have utility in reporting adherence (tolerability) of exercise treatment in cancer. METHODS:Using a retrospective analysis of a randomized trial, 25 prostate cancer patients received an aerobic training regimen of 72 supervised treadmill walking sessions delivered thrice weekly between 55% and 100% of exercise capacity for 24 consecutive weeks. Treatment adherence (tolerability) was assessed using conventional (lost to follow-up and attendance) and exploratory (e.g., permanent discontinuation, dose modification, and relative dose intensity) outcomes. RESULTS:The mean total cumulative \"planned\" and \"completed\" dose was 200.7 ± 47.6 and 153.8 ± 68.8 MET·h, respectively, equating to a mean relative dose intensity of 77% ± 24%. Two patients (8%) were lost to follow-up, and mean attendance was 79%. A total of 6 (24%) of 25 patients permanently discontinued aerobic training before week 24. Aerobic training was interrupted (missing ?3 consecutive sessions) or dose reduced in a total of 11 (44%) and 24 (96%) patients, respectively; a total 185 (10%) of 1800 training sessions required dose reduction owing to both health-related (all nonserious) and non-health-related adverse events. Eighteen (72%) patients required at least one session to be terminated early; a total of 59 (3%) sessions required early termination. CONCLUSIONS:Novel methods for the conduct and reporting of exercise treatment adherence and tolerability may provide important information beyond conventional metrics in patients with cancer."],"journal":["Medicine and science in sports and exercise"],"pubmed_title":["Novel Methods for Reporting of Exercise Dose and Adherence: An Exploratory Analysis."],"pmcid":["PMC5953772"],"funding_grant_id":["P30 CA008748","R21 CA133895"],"pubmed_authors":["Nilsen TS","Thomas S","Capaci C","Jones LW","Scott JM","Michalski M","Eves ND","Sasso J","Herndon JE"],"additional_accession":[]},"is_claimable":false,"name":"Novel Methods for Reporting of Exercise Dose and Adherence: An Exploratory Analysis.","description":"PURPOSE:The purpose of this study was to explore whether methods adapted from oncology pharmacological trials have utility in reporting adherence (tolerability) of exercise treatment in cancer. METHODS:Using a retrospective analysis of a randomized trial, 25 prostate cancer patients received an aerobic training regimen of 72 supervised treadmill walking sessions delivered thrice weekly between 55% and 100% of exercise capacity for 24 consecutive weeks. Treatment adherence (tolerability) was assessed using conventional (lost to follow-up and attendance) and exploratory (e.g., permanent discontinuation, dose modification, and relative dose intensity) outcomes. RESULTS:The mean total cumulative \"planned\" and \"completed\" dose was 200.7 ± 47.6 and 153.8 ± 68.8 MET·h, respectively, equating to a mean relative dose intensity of 77% ± 24%. Two patients (8%) were lost to follow-up, and mean attendance was 79%. A total of 6 (24%) of 25 patients permanently discontinued aerobic training before week 24. Aerobic training was interrupted (missing ?3 consecutive sessions) or dose reduced in a total of 11 (44%) and 24 (96%) patients, respectively; a total 185 (10%) of 1800 training sessions required dose reduction owing to both health-related (all nonserious) and non-health-related adverse events. Eighteen (72%) patients required at least one session to be terminated early; a total of 59 (3%) sessions required early termination. CONCLUSIONS:Novel methods for the conduct and reporting of exercise treatment adherence and tolerability may provide important information beyond conventional metrics in patients with cancer.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jun","modification":"2020-10-29T13:38:02Z","creation":"2019-07-01T13:38:35Z"},"accession":"S-EPMC5953772","cross_references":{"pubmed":["29315168"],"doi":["10.1249/MSS.0000000000001545","10.1249/mss.0000000000001545"]}}